(Q38725366)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852913%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

review article

1 reference

title

Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852913%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

main subject

chronic myeloid leukemia

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852913%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Paolo Vigneri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852913%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Stefania Stella

2

1 reference

ORCID Public Data File 2021

author name string

Antonio Spitaleri

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852913%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Maria Stella Pennisi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852913%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Francesco Di Raimondo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852913%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

1 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852913%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

7 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852913%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852913%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852913%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

273-278

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852913%20AND%20SRC:MED&resulttype=core&format=json

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

7 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Chromosomal localization of human cellular homologues of two viral oncogenes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Structural organization of the bcr gene and its role in the Ph' translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

21 January 2018

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Part I: Milestones in personalised medicine--imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Management of chronic myeloid leukemia: targets for molecular therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Chronic myeloid leukaemia as a model of disease evolution in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

OCT1 and imatinib transport in CML: is it clinically relevant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

The interferon-alpha revival in CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Is there a best TKI for chronic phase CML?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

How I treat newly diagnosed chronic myeloid leukemia in 2015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

The choice of first-line chronic myelogenous leukemia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2016.1151356

10.1586/14737140.2016.1151356

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26852913%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference